Flurpiridaz F-18 — Active Pharmaceutical Ingredient

Flurpiridaz F-18 is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: SOLUTION. Routes: INTRAVENOUS.

This content is for informational purposes only. Always consult a healthcare professional.

Flurpiridaz F-18 (1 brand name, 1 dosage form, 1 route)

Available dosage forms: SOLUTION.

Routes of administration: INTRAVENOUS.

Brand Names

  • FLYRCADO

Indications and Usage

FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None.

Adverse Reactions

The following serious adverse reactions are described elsewhere in the labeling: Risks Associated with Exercise or Pharmacologic Stress [see Warnings and Precautions (5.1)]

Mechanism of Action

Flurpiridaz F 18 is an analog of the mitochondrial complex 1 (MC-1) inhibitor, pyridaben. Flurpiridaz F 18 is extracted by the myocardium proportional to the blood flow and binds to heart tissue that has biologically active mitochondria. Therefore, radioactivity in viable myocardium is higher than in infarcted tissue.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.